ROBERT M CONRY
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- ANNISTON, AL
- NPI
- 1548203235
- Received
- $142,532 in 301 records, 2019 to 2025
- As principal investigator
- $747,002 of research payments to others in 89 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 45 | $1,693 |
| 2024 | General payment | 64 | $1,999 |
| 2023 | General payment | 38 | $957 |
| 2022 | General payment | 45 | $1,955 |
| 2021 | General payment | 3 | $877 |
| 2020 | General payment | 3 | $4,475 |
| 2019 | General payment | 103 | $130,575 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 42 | $124,432 |
| Travel and Lodging | 37 | $7,034 |
| Food and Beverage | 189 | $4,765 |
| Consulting Fee | 7 | $4,120 |
| Long term medical supply or device loan | 25 | $2,165 |
| Education | 1 | $15 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-12-18 | Celgene Corporation | $23 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-12-10 | Celgene Corporation | $21 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-12-05 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-11-26 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-11-14 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-11-07 | Gilead Sciences, Inc. | $19 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-10-24 | ARRAY BIOPHARMA INC | $24 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-10-23 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-10-23 | Gilead Sciences, Inc. | $21 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-10-03 | Takeda Pharmaceuticals U.S.A., Inc. | $19 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2025 | |
| 2025-09-19 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-08-27 | Stemline Therapeutics Inc. | $24 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-08-21 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-08-20 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-08-14 | Daiichi Sankyo Inc. | $27 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-07-25 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-07-24 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-07-16 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-27 | BeOne Medicines USA, Inc. | $15 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-06-12 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-06-11 | ARRAY BIOPHARMA INC | $22 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-06-11 | Gilead Sciences, Inc. | $19 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-05-29 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-05-19 | Novartis Pharmaceuticals Corporation | $8 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-05-15 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-05-06 | Gilead Sciences, Inc. | $24 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-04-24 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-04-17 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-04-16 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-04-10 | Daiichi Sankyo Inc. | $17 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-04-09 | Janssen Biotech, Inc. | $24 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-03-26 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-03-25 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-03-19 | Deciphera Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-02-28 | Daiichi Sankyo Inc. | $16 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-02-27 | Celgene Corporation | $20 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2025 | |
| 2025-02-21 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-02-21 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-02-12 | Stemline Therapeutics Inc. | $27 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-01-31 | Daiichi Sankyo Inc. | $28 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-01-23 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-01-16 | GlaxoSmithKline, LLC. | $23 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-01-07 | Gilead Sciences, Inc. | $23 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-01-02 | ARRAY BIOPHARMA INC | $20 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2025 | |
| 2024-12-18 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-12-12 | Novartis Pharmaceuticals Corporation | $28 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-12-10 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-11-14 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-11-14 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-13 | Merck Sharp & Dohme LLC | $9 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-06 | Daiichi Sankyo Inc. | $29 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-10-17 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-10-07 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-09-27 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-09-12 | E.R. Squibb & Sons, L.L.C. | $13 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2024 | |
| 2024-09-04 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2024 | |
| 2024-09-04 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2024 | |
| 2024-08-28 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2024 | |
| 2024-08-23 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-08-21 | Takeda Pharmaceuticals U.S.A., Inc. | $25 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2024 | |
| 2024-08-01 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-07-26 | Merck Sharp & Dohme LLC | $20 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-07-25 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2024 | |
| 2024-07-23 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-07-23 | Novartis Pharmaceuticals Corporation | $2 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-07-19 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2024 | |
| 2024-07-17 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-07-15 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-06-28 | ARRAY BIOPHARMA INC | $20 | Food and Beverage | In-kind items and services | XALKORI Drug, ONCOLOGY | 2024 | |
| 2024-06-27 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | MEKINIST Drug, Oncology | 2024 | |
| 2024-06-27 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | MEKINIST Drug, Oncology | 2024 | |
| 2024-06-21 | Gilead Sciences, Inc. | $27 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-19 | E.R. Squibb & Sons, L.L.C. | $23 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2024 | |
| 2024-06-13 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-06-08 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2024 | |
| 2024-06-06 | Novartis Pharmaceuticals Corporation | $26 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-06-04 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2024 | |
| 2024-05-29 | Merck Sharp & Dohme LLC | $29 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-05-23 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-05-23 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-05-16 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-05-10 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2024 | |
| 2024-05-08 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-05-03 | PFIZER INC. | $60 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2024 | |
| 2024-05-03 | PFIZER INC. | $60 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2024 | |
| 2024-05-02 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-05-02 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2024 | |
| 2024-04-29 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-04-25 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-04-25 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-04-18 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-04-11 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-03-27 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2024 | |
| 2024-03-15 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-03-07 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-03-02 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-02-29 | Novartis Pharmaceuticals Corporation | $10 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-02-16 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-02-16 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2024 | |
| 2024-02-15 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | OXBRYTA Drug, HEMATOLOGY | 2024 | |
| 2024-02-07 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-02-02 | ARRAY BIOPHARMA INC | $11 | Food and Beverage | In-kind items and services | XALKORI Drug, ONCOLOGY | 2024 | |
| 2024-01-31 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-01-26 | PFIZER INC. | $29 | Food and Beverage | In-kind items and services | TUKYSA Drug, Oncology | 2024 | |
| 2024-01-24 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2024 | |
| 2024-01-19 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2024 | |
| 2024-01-18 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-01-04 | Eisai Inc. | $16 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2024 | |
| 2023-12-13 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2023 | |
| 2023-11-30 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2023 | |
| 2023-11-02 | Merck Sharp & Dohme LLC | $16 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-11-01 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-10-26 | Celgene Corporation | $15 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2023 | |
| 2023-10-25 | Novartis Pharmaceuticals Corporation | $25 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2023 | |
| 2023-10-06 | Celgene Corporation | $19 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2023 | |
| 2023-10-05 | Kite Pharma, Inc. | $14 | Food and Beverage | In-kind items and services | Yescarta Drug, CELLT | 2023 | |
| 2023-09-14 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2023 | |
| 2023-09-07 | Pharmacyclics LLC, an AbbVie Company | $19 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2023 | |
| 2023-08-24 | Takeda Pharmaceuticals U.S.A., Inc. | $17 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2023 | |
| 2023-08-18 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2023 | |
| 2023-08-11 | Daiichi Sankyo Inc. | $27 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2023 | |
| 2023-08-05 | Pharmacyclics LLC, an AbbVie Company | $18 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2023 | |
| 2023-07-27 | Regeneron Healthcare Solutions, Inc. | $15 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2023 | |
| 2023-06-30 | Celgene Corporation | $16 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2023 | |
| 2023-06-23 | Novartis Pharmaceuticals Corporation | $25 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2023 | |
| 2023-06-22 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-06-15 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | PIQRAY Drug, Oncology | 2023 | |
| 2023-05-31 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | 2023 | ||
| 2023-05-31 | ARRAY BIOPHARMA INC | $20 | Food and Beverage | In-kind items and services | XALKORI Drug, ONCOLOGY | 2023 | |
| 2023-05-25 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-05-24 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | OXBRYTA Drug, HEMATOLOGY | 2023 | |
| 2023-05-04 | Aveo Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2023 | |
| 2023-04-28 | Pharmacyclics LLC, an AbbVie Company | $18 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2023 | |
| 2023-04-22 | Deciphera Pharmaceuticals Inc. | $26 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2023 | |
| 2023-04-19 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2023 | |
| 2023-04-05 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-04-04 | Galt Pharmaceuticals, LLC | $128 | Food and Beverage (14 payments) | In-kind items and services | Orphengesic Forte Drug, Pain | 2023 | |
| 2023-03-29 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-03-23 | Kite Pharma, Inc. | $14 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-03-22 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-03-09 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-03-02 | Blueprint Medicines Corporation | $21 | Food and Beverage | In-kind items and services | AYVAKIT Drug, Oncology / Rare Diseases | 2023 | |
| 2023-02-23 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | TASIGNA Drug, Oncology | 2023 | |
| 2023-01-26 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2023 | |
| 2023-01-25 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-01-13 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2023 | |
| 2022-12-30 | Celgene Corporation | $15 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2022 | |
| 2022-12-28 | ADC THERAPEUTICS AMERICA, INC. | $17 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-12-21 | Merck Sharp & Dohme LLC | $2 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-12-15 | Agios Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-12-09 | Deciphera Pharmaceuticals Inc. | $26 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2022 | |
| 2022-12-08 | ARRAY BIOPHARMA INC | $17 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2022 | |
| 2022-11-30 | Celgene Corporation | $18 | Food and Beverage | Cash or cash equivalent | Pomalyst Drug, Hematology | 2022 | |
| 2022-11-30 | Celgene Corporation | $1 | Food and Beverage | Cash or cash equivalent | Pomalyst Drug, Hematology | 2022 | |
| 2022-11-10 | Karyopharm Therapeutics Inc. | $21 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2022 | |
| 2022-11-09 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-10-11 | Pharmacyclics LLC, an AbbVie Company | $19 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2022 | |
| 2022-10-05 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-09-30 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2022 | |
| 2022-09-30 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2022 | |
| 2022-09-28 | Daiichi Sankyo Inc. | $20 | Food and Beverage | In-kind items and services | ENHERTU Drug, ONCOLOGY | 2022 | |
| 2022-09-21 | Deciphera Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2022 | |
| 2022-09-16 | Janssen Biotech, Inc. | $24 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2022 | |
| 2022-09-07 | Celgene Corporation | $24 | Food and Beverage | Cash or cash equivalent | Pomalyst Drug, Hematology | 2022 | |
| 2022-08-25 | Celgene Corporation | $15 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2022 | |
| 2022-08-16 | TAIHO ONCOLOGY, INC. | $22 | Food and Beverage | In-kind items and services | LONSURF Drug, Oncology | 2022 | |
| 2022-08-11 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-08-10 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | PROMACTA Drug, ONCOLOGY | 2022 | |
| 2022-08-04 | Pharmacyclics LLC, an AbbVie Company | $15 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2022 | |
| 2022-07-20 | SEAGEN INC. | $19 | Food and Beverage | In-kind items and services | ADCETRIS Biological, Oncology | 2022 | |
| 2022-07-14 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-07-12 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2022 | |
| 2022-06-30 | Eisai Inc. | $18 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2022 | |
| 2022-06-29 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-06-29 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-06-22 | Merck Sharp & Dohme LLC | $18 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-06-03 | Pharmacyclics LLC, an AbbVie Company | $15 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2022 | |
| 2022-06-01 | GLOBAL BLOOD THERAPEUTICS, INC. | $16 | Food and Beverage | In-kind items and services | OXBRYTA Drug, Sickle Cell Disease | 2022 | |
| 2022-05-26 | SEAGEN INC. | $18 | Food and Beverage | In-kind items and services | ADCETRIS Biological, Oncology | 2022 | |
| 2022-04-27 | EMD Serono, Inc. | $13 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-04-22 | E.R. Squibb & Sons, L.L.C. | $15 | Education | In-kind items and services | 2022 | ||
| 2022-04-15 | SEAGEN INC. | $13 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2022 | |
| 2022-04-14 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-04-14 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-04-05 | Exelixis Inc. | $27 | Food and Beverage | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-04-01 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2022 | |
| 2022-03-23 | Eisai Inc. | $20 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2022 | |
| 2022-03-21 | Celgene Corporation | $600 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-03-21 | Celgene Corporation | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-03-21 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-03-03 | Rigel Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | Tavalisse Drug, Hematology | 2022 | |
| 2021-12-16 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-06-09 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-02-01 | GENZYME CORPORATION | $822 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, Oncology | 2021 | |
| 2020-10-23 | PFIZER INC. | $3,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | 2020 | |
| 2020-03-17 | Merck Sharp & Dohme LLC | $17 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-03-06 | GENZYME CORPORATION | $1,058 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2019-12-11 | Regeneron Healthcare Solutions, Inc. | $1,006 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2019 | |
| 2019-11-21 | Novartis Pharmaceuticals Corporation | $3,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MEKINIST Drug, ONCOLOGY | 2019 |
The latest 200 records of 301.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-09-01 | Novartis Pharmaceuticals Corporation | ARTHRITIS CLINICAL INTERVENTION PROGRAM UNIVERSITY OF ALABAMA | $24,635 | COMBIad A phase III randomized double blind study of dabrafenib GSK2118436 in COMBInation with trametinib GSK1120212 ver | 2025 |
| 2024-05-06 | Novartis Pharmaceuticals Corporation | ARTHRITIS CLINICAL INTERVENTION PROGRAM UNIVERSITY OF ALABAMA | $5,977 | COMBIad A phase III randomized double blind study of dabrafenib GSK2118436 in COMBInation with trametinib GSK1120212 ver | 2024 |
| 2023-05-29 | Novartis Pharmaceuticals Corporation | ARTHRITIS CLINICAL INTERVENTION PROGRAM UNIVERSITY OF ALABAMA | $3,187 | COMBIad A phase III randomized double blind study of dabrafenib GSK2118436 in COMBInation with trametinib GSK1120212 ver | 2023 |
| 2022-02-03 | Novartis Pharmaceuticals Corporation | University Of Alabama Hospital | $2,967 | COMBIAD A PHASE III RANDOMIZED DOUBLE BLIND STUDY OF DABRAFENIB GSK2118436 IN COMBINATION WITH TRAMETINIB GSK1120212 VER | 2022 |
| 2021-06-23 | Novartis Pharmaceuticals Corporation | VECTOR ONCOLOGY LLC | $460 | A PHASE III RANDOMIZED 3 ARM OPEN LABEL MULTICENTER STUDY OF LGX818 PLUS MEK162 AND LGX818 MONOTHERAPY COMPARED WITH VEM | 2021 |
| 2021-04-23 | Amgen Inc. | UNIVERSITY OF ALABAMA AT BIRMINGHAM THE KIRKLIN CLINIC AT ACTON ROAD | $6,400 | Pharmacovigilance study of herpes symptoms among patients treated with IMLYGIC. | 2021 |
| 2020-12-24 | Amgen Inc. | University Of Alabama Hospital | $142 | P2 Neo-adjuvant melanoma | 2020 |
| 2020-12-24 | Amgen Inc. | University Of Alabama Hospital | $302 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-11-20 | Genentech, Inc. | University Of Alabama Hospital | $1,167 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-10-14 | Amgen Inc. | University Of Alabama Hospital | $84 | P2 Neo-adjuvant melanoma | 2020 |
| 2020-09-28 | Dynavax Technologies Corporation | University Of Alabama Hospital | $3,294 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-09-28 | Dynavax Technologies Corporation | University Of Alabama Hospital | $2,144 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-08-06 | Novartis Pharmaceuticals Corporation | University Of Alabama Hospital | $2,225 | COMBIAD A PHASE III RANDOMIZED DOUBLE BLIND STUDY OF DABRAFENIB GSK2118436 IN COMBINATION WITH TRAMETINIB GSK1120212 VER | 2020 |
| 2020-07-13 | Novartis Pharmaceuticals Corporation | UNIVERSITY OF ALABAMA AT BIRMINGHAM | $7,809 | A PHASE III RANDOMIZED 3 ARM OPEN LABEL MULTICENTER STUDY OF LGX818 PLUS MEK162 AND LGX818 MONOTHERAPY COMPARED WITH VEM | 2020 |
| 2020-07-01 | Genentech, Inc. | University Of Alabama Hospital | $3,525 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-06-20 | Amgen Inc. | University Of Alabama Hospital | $14,405 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-06-08 | Dynavax Technologies Corporation | University Of Alabama Hospital | $3,861 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-06-08 | Dynavax Technologies Corporation | University Of Alabama Hospital | $5,645 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-06-08 | Dynavax Technologies Corporation | University Of Alabama Hospital | $99 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-05-27 | Genentech, Inc. | University Of Alabama Hospital | $500 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-05-20 | Amgen Inc. | University Of Alabama Hospital | $1,420 | P2 Neo-adjuvant melanoma | 2020 |
| 2020-05-01 | Amgen Inc. | University Of Alabama Hospital | $170 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-05-01 | Amgen Inc. | University Of Alabama Hospital | $141 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-05-01 | Genentech, Inc. | University Of Alabama Hospital | $7,686 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-04-02 | Genentech, Inc. | University Of Alabama Hospital | $45,470 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-04-02 | Genentech, Inc. | University Of Alabama Hospital | $1,143 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-03-13 | Genentech, Inc. | University Of Alabama Hospital | $2,081 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-03-07 | Amgen Inc. | University Of Alabama Hospital | $27,588 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-03-05 | Novartis Pharmaceuticals Corporation | University Of Alabama Hospital | $4,539 | COMBIV A PHASE III RANDOMISED OPEN LABEL STUDY COMPARING THE COMBINATION OF THE BRAF INHIBITOR DABRAFENIB AND THE MEK IN | 2020 |
| 2020-03-02 | Dynavax Technologies Corporation | University Of Alabama Hospital | $10,675 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-02-21 | Amgen Inc. | University Of Alabama Hospital | $1,142 | P2 Neo-adjuvant melanoma | 2020 |
| 2020-02-01 | Amgen Inc. | University Of Alabama Hospital | $14 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-02-01 | Amgen Inc. | University Of Alabama Hospital | $424 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-02-01 | Amgen Inc. | University Of Alabama Hospital | $511 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-01-06 | Dynavax Technologies Corporation | University Of Alabama Hospital | $1,947 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-01-06 | Dynavax Technologies Corporation | University Of Alabama Hospital | $3,103 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-01-06 | Dynavax Technologies Corporation | University Of Alabama Hospital | $2,664 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-01-06 | Dynavax Technologies Corporation | University Of Alabama Hospital | $260 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-01-06 | Dynavax Technologies Corporation | University Of Alabama Hospital | $130 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-01-02 | ARRAY BIOPHARMA INC | University Of Alabama Hospital | $1,000 | A 2PART PHASE III RANDOMIZED OPEN LABEL MULTICENTER STUDY OF LGX818 PLUS MEK162 VERSUS VEMURAFENIB AND LGX818 MONOTHERAP | 2020 |
| 2020-01-02 | ARRAY BIOPHARMA INC | University Of Alabama Hospital | $4,000 | A 2PART PHASE III RANDOMIZED OPEN LABEL MULTICENTER STUDY OF LGX818 PLUS MEK162 VERSUS VEMURAFENIB AND LGX818 MONOTHERAP | 2020 |
| 2020-01-01 | Amgen Inc. | University Of Alabama Hospital | $9,036 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2019-12-24 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $284 | P2 Neo-adjuvant melanoma | 2019 |
| 2019-12-05 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $16,254 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-12-04 | E.R. Squibb & Sons, L.L.C. | UNIVERSITY OF ALABAMA HOSPITAL | $2,126 | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2019 |
| 2019-11-14 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $185 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-11-04 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $2,522 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-10-28 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $5,612 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-10-24 | ARRAY BIOPHARMA INC | UNIVERSITY OF ALABAMA HOSPITAL | $2,741 | A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monothe | 2019 |
| 2019-10-07 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $390 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-10-07 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $5,780 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-10-07 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $2,028 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-09-16 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $12,573 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-08-06 | ARRAY BIOPHARMA INC | UNIVERSITY OF ALABAMA HOSPITAL | $250 | A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monothe | 2019 |
| 2019-08-01 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $511 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-08-01 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $21 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-08-01 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $628 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-08-01 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $424 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-07-29 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $10,910 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-07-25 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $13,831 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-07-22 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $429 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-07-22 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $99 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-07-16 | Novartis Pharmaceuticals Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $2,820 | COMBIV A PHASE III RANDOMISED OPEN LABEL STUDY COMPARING THE COMBINATION OF THE BRAF INHIBITOR DABRAFENIB AND THE MEK IN | 2019 |
| 2019-06-06 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $140 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-06-05 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $517 | P2 Neo-adjuvant melanoma | 2019 |
| 2019-06-04 | ARRAY BIOPHARMA INC | UNIVERSITY OF ALABAMA HOSPITAL | $794 | A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monothe | 2019 |
| 2019-06-03 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $390 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-05-20 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $4,359 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-05-20 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $41,275 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-05-20 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $447 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-05-15 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $6,994 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-05-09 | Novartis Pharmaceuticals Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $2,307 | COMBIAD A PHASE III RANDOMIZED DOUBLE BLIND STUDY OF DABRAFENIB GSK2118436 IN COMBINATION WITH TRAMETINIB GSK1120212 VER | 2019 |
| 2019-05-02 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $7,686 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-04-25 | Novartis Pharmaceuticals Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $5,324 | GSK2118436 A PHASE III RANDOMIZED OPEN LABEL STUDY COMPARING GSK2118436 TO DTIC IN PREVIOUSLY UNTREATED SUBJECTS WITH BR | 2019 |
| 2019-04-07 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $148,140 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-04-01 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $9,240 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-03-26 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $19,767 | BRAF IN ADJUVANT | 2019 |
| 2019-03-11 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $6,739 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-03-08 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $13,989 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-03-04 | Amgen Inc. | UNIVERSITY OF ALABAMA AT BIRMINGHAM THE KIRKLIN CLINIC AT ACTON ROAD | $1,714 | Chart Review study of real-world IMLYGIC use | 2019 |
| 2019-03-01 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $10,536 | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-02-21 | ARRAY BIOPHARMA INC | UNIVERSITY OF ALABAMA HOSPITAL | $397 | A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monothe | 2019 |
| 2019-02-20 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $245 | BRAF IN ADJUVANT | 2019 |
| 2019-02-20 | Genentech, Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $1,630 | BRAF IN ADJUVANT | 2019 |
| 2019-02-01 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $91,862 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-02-01 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $1,256 | P1/3 talimogene laherparepvec + PD-1 in recurrent/metastatic SCCHN | 2019 |
| 2019-01-28 | Dynavax Technologies Corporation | UNIVERSITY OF ALABAMA HOSPITAL | $130 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-01-26 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $71,775 | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2019 |
| 2019-01-25 | Amgen Inc. | UNIVERSITY OF ALABAMA HOSPITAL | $4,942 | P2 Neo-adjuvant melanoma | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Anniston, AL, county Calhoun County, AL, state Alabama; placed by its city name.
| Measure | Place (city or town) Anniston, AL | County Calhoun County, AL | State Alabama |
|---|---|---|---|
| Population B01003 | 21,271 | 116,090 | 5,086,768 |
| Population, 2020 census P1 | 21,564 | 116,441 | 5,024,279 |
| Median age B01002 | 42.8 | 39.3 | 39.3 |
| Under 18 B01001 | 20.8% | 21.4% | 22.2% |
| 65 and over B01001 | 22.4% | 18.2% | 17.8% |
| Households B11001 | 8,881 | 45,015 | 1,997,247 |
| Foreign born B05002 | 2.7% | 2.9% | 4.0% |
| Median household income B19013 | $46,668 | $55,029 | $63,999 |
| Median family income B19113 | $63,659 | $70,243 | $83,032 |
| Per capita income B19301 | $30,565 | $30,275 | $36,087 |
| Poverty rate B17001 | 20.6% | 17.9% | 15.6% |
| Unemployment rate B23025 | 6.4% | 6.0% | 4.7% |
| Civilian labor force B23025 | 8,708 | 52,623 | 2,367,787 |
| Mean commute (minutes) B08013 | 23.8 | 25.2 | 25.5 |
| Bachelor's degree or higher B15003 | 20.5% | 20.6% | 28.4% |
| Housing units B25001 | 11,420 | 53,361 | 2,337,265 |
| Owner-occupied B25003 | 58.5% | 70.3% | 70.2% |
| Renters B25003 | 41.5% | 29.7% | 29.8% |
| Median home value B25077 | $158,800 | $156,600 | $209,900 |
| Median gross rent B25064 | $799 | $826 | $1,007 |
| White, not Hispanic B03002 | 41.5% | 69.3% | 63.4% |
| Black B03002 | 50.5% | 21.6% | 25.6% |
| Hispanic or Latino B03002 | 4.2% | 4.6% | 5.6% |
| Asian B03002 | 0.4% | 0.8% | 1.4% |
| American Indian and Alaska Native B03002 | 0.3% | 0.2% | 0.3% |
Economy now FRED unemployment 3.5% in Sep 2026 (2.8% a year earlier); per capita personal income $59,754 in 2025, up 30% in five years (+4.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Anniston, AL.
Comments